No products in the cart.
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
Tag: Atezolizumab
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology.
Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
1. The pathologic response rate was similar in the atezolizumab treatment group as compared to placebo. 2. There were more ...
Addition of atezolizumab to FOLFOXIRI and bevacizumab led to limited increase in survival in metastatic colorectal cancer
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4 ...
Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as compared to placebo 2. The combination arm had ...
#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer
Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. Grade 3 ...
Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer
1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2. ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.